Thalidomide Market

Thalidomide API market is projected to grow at a CAGR of 4.8% between 2025 and 2035, the market growth is primarily driven by the increasing prevalence of multiple myeloma and leprosy-related conditions such as erythema nodosum leprosum (ENL), for which thalidomide remains a key treatment. The market is also benefiting from ongoing clinical research exploring new therapeutic applications, particularly in autoimmune disorders and cancer.

By application, the multiple myeloma segment dominates the market, accounting for the largest revenue share in 2023 and expected to retain its lead through 2030. This is due to thalidomide’s proven efficacy in combination therapy regimens for newly diagnosed and relapsed/refractory cases. The ENL segment also holds a significant share, particularly in low- and middle-income countries where the disease burden is higher. Off-label and research-based uses in Crohn’s disease, HIV-related complications, and other niche indications are expected to grow steadily.

Geographically, North America holds the largest market share, led by the United States, due to strong regulatory oversight, high adoption rates of thalidomide-containing regimens, and ongoing drug development activity. However, Asia-Pacific, particularly India and China, is expected to exhibit the fastest growth, driven by increasing pharmaceutical manufacturing capacities, lower production costs, and a higher incidence of ENL in some regions.

Prominent players in the market include Celgene Corporation (now part of Bristol-Myers Squibb), which holds proprietary rights for branded formulations in several countries, along with prominent generic API manufacturers such as Zydus Lifesciences, Natco Pharma, and Cipla. These companies are increasingly focused on API production for both domestic and international markets, catering to rising demand and regulatory requirements in both developed and emerging regions.